TO CORRECT OR NOT TO CORRECT (FOR TREATMENT): ESTIMATING PRETREATMENT LDL-C CONCENTRATIONS IN GENETICALLY CHARACTERIZED PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA ON LIPID-LOWERING MEDICATION

被引：0

作者：

Stevens, Christophe ^{[1
]}

Elshorbagy, Amany ^{[1
]}

Vallejo-Vaz, Antonio ^{[1
,2
,3
,4
]}

Dharmayat, Kanika ^{[1
]}

Lyons, Alexander ^{[1
]}

Bourbon, Mafalda ^{[5
,6
,7
]}

Chora, Joana ^{[6
,7
]}

Humphries, Steve ^{[8
]}

Catapano, Alberico ^{[9
,10
]}

Hovingh, G. ^{[11
]}

Mata, Pedro ^{[12
]}

Santos, Raul ^{[13
]}

Soran, Handrean ^{[14
]}

Watts, Gerald ^{[15
,16
]}

Raal, Frederick J. ^{[17
]}

Freiberger, Tomas ^{[18
]}

Ray, Kausik ^{[1
]}

机构：

[1] Imperial Coll London, Sch Publ Hlth, Dept Primary Care & Publ Hlth, Imperial Ctr Cardiovasc Dis Prevent, London, England

[2] Inst Salud Carlos III, Ctr Invest Biomed Red CIBER Epidemiol & Salud Pub, Seville, Spain

[3] Univ Seville, Dept Med, Fac Med, Seville, Spain

[4] Univ Seville, Inst Biomedicina Sevilla, Clin Epidemiol & Vasc Risk, CSIC,IBiS Hosp Univ Virgen del Rocio, Seville, Spain

[5] Inst Nacl Saude Doutor Ricardo Jorge, Unidade Invest & Desenvolvimento, Grupo Invest Cardiovasc, Dept Promocao Saude & Prevencao Doencas Nao Trans, Lisbon, Portugal

[6] Univ Lisbon, BioISI Biosyst & Integrat Sci, Fac Ciencias, Lisbon, Portugal

[7] Inst Nacl Saude Doutor Ricardo Jorge, Lisbon, Portugal

[8] UCL, Inst Cardiovasc Sci, London, England

[9] Epidemiol & Prevent Pharmacol Serv SEFAP, Dept Pharmacol & Biomol Sci, Milan, Italy

[10] IRCCS MultiMed, Sesto San Giovanni, MI, Italy

[11] Amsterdam UMC, Vasc Med, Amsterdam, Netherlands

[12] Fdn Hipercolesterolemia Familiar, Madrid, Spain

[13] Univ Sao Paulo, Cardiopneumol, Sao Paulo, Brazil

[14] Manchester Univ NHS Fdn Trust, Manchester, England

[15] Univ Western Australia, Sch Med, Perth, Australia

[16] Univ Western Australia, Cardiometab Serv, Sch Med, Perth, Australia

[17] Univ Witwatersrand, Carbohydrate & Lipid Metab Res Unit, Fac Hlth Sci, Johannesburg, South Africa

[18] Masaryk Univ, Ctr Cardiovasc Surg & Transplantat, Brno, Czech Republic

来源：

ATHEROSCLEROSIS | 2024年 / 395卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SaaG031

引用

页数：2

共 29 条

[1] Evinacumab Lowers LDL-C in Patients With Homozygous Familial Hypercholesterolemia Irrespective of Background Lipid-lowering Medication
Raal, Frederick J.
Rosenson, Robert S.
Reeskamp, Laurens F.
Hovingh, G. Kees
Kastelein, John J.
Rubba, Paolo
Ali, Shazia
Banerjee, Poulabi
Chan, Kuo-Chen
Khilla, Nagwa
McGinniss, Jennifer
Pordy, Robert
Zhang, Yi
Gaudet, Daniel
[J]. CIRCULATION, 2020, 142
[2] APPROACHES TO LDL-C MANAGEMENT IN CHILDREN AND ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA: ANALYSIS ON OVER 3000 INDIVIDUALS RECEIVING LIPID-LOWERING MEDICATION IN THE FHSC REGISTRY
Dharmayat, K.
Stevens, C.
Elshorbagy, A.
Brandts, J.
Lyons, A.
Catapano, A.
Freiberger, T.
Hovingh, G. K.
Mata, P.
Santos, R.
Soran, H.
Watts, G.
Raal, F.
Ray, K.
Vallejo-Vaz, A.
[J]. ATHEROSCLEROSIS, 2023, 379
[3] Lipid-lowering therapy in patients with a 'normal' LDL-C Authors' response
Nelson, Adam
Nicholls, Stephen
[J]. AUSTRALIAN PRESCRIBER, 2024, 47 (03) : 94 - 94
[4] LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA
Pan, Yuesong
Wangqin, Runqi
Li, Hao
Jin, Aoming
Li, Jiejie
Lin, Jinxi
Meng, Xia
Xian, Ying
Laskowitz, Daniel T.
Wang, Yongjun
[J]. STROKE AND VASCULAR NEUROLOGY, 2022, 7 (04) : 276 - 284
[5] TREATMENT PATTERNS AND LDL-C CONTROL IN VERY HIGH-RISK PATIENTS RECEIVING LIPID-LOWERING THERAPY IN THE UNITED KINGDOM
Beaini, Y.
Danese, M.
Sidelnikov, E.
Villa, G.
Catterick, D.
Iqbal, M.
Gleeson, M.
Lubeck, D.
Patel, J.
[J]. VALUE IN HEALTH, 2020, 23 : S499 - S500
[6] LDL-C goal achievement and lipid-lowering therapy in patients by atherosclerotic cardiovascular disease subtype: the SANTORINI study
Catapano, A. L.
Manu, M. C.
Burden, A.
Ray, K. K.
[J]. EUROPEAN HEART JOURNAL, 2022, 43 : 2373 - 2373
[7] LDL-c-linked SNPs are associated with LDL-c and myocardial infarction despite lipid-lowering therapy in patients with established vascular disease
van de Woestijne, Anton P.
van der Graaf, Yolanda
de Bakker, Paul I. W.
Asselbergs, Folkert W.
de Borst, Gert Jan
Algra, Ale
Spiering, Wilko
Visseren, Frank L. J.
[J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2014, 44 (02) : 184 - 191
[8] CORRELATION OF NON-HDL-C AND LDL-C WITH APOB DURING LIPID-LOWERING THERAPY IN PATIENTS WITH COMBINED HYPERLIPIDEMIA (HL)
Grundy, S.
Vega, G.
Tomassini, J.
Tershakovec, A.
[J]. ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
[9] ATTAINMENT OF LDL-C TREATMENT TARGET IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS: A THEORETICAL MODEL EXPLORING EFFICACY OF CURRENT AND NOVEL LIPID LOWERING THERAPIES
Hartgers, M. L.
Besseling, J.
Hovingh, G. K.
[J]. ATHEROSCLEROSIS, 2016, 252 : E43 - E44
[10] THE EFFECT OF AN INTENSIVE LIPID-LOWERING THERAPY PROTOCOL ON ACHIEVING TARGET LDL-C LEVELS IN PATIENTS WITH ACUTE CORONARY SYNDROME
Seiyama, Kosuke
Oka, Akihiro
Takagi, Wataru
Okada, Tomoaki
Nosaka, Kazumasa
Miyoshi, Toru
Doi, Masayuki
[J]. ATHEROSCLEROSIS, 2024, 395

← 1 2 3 →